Hanpeptide Biopharmaceutical Group Co., LTD is a high-tech enterprise focusing on the development of synthetic biology technology, mainly engaged in the design, production and sales of new gene recombinant polypeptide drugs.The company has 2,000 square meters of research and development base, production base and scientific research center in Shandong, Jiangsu.With a first-class research and development team composed of overseas returnees and domestic leaders, the company has set up and completed gene editing, enzyme engineering, high-throughput peptide synthesis and quality management and control laboratories.Based on the rational design of drugs, combined with advanced synthetic biology technology, the "green intelligence" of gene recombination polypeptide drugs, new antibody drugs and active small molecule compounds is realized.
● Based on the principle of "complementary advantages, mutual benefits, serving local communities and common development", Hanpeptide Biomedical Group Co., Ltd. and Shandong University reached an agreement on long-term cooperation bet
● A platform for the research and development of recombinant polypeptide drugs and a screening platform for novel anti-tumor drugs were established, and the fermentation technology of polyglutamic acid and antialcoholic bacteria was established
● The projects under development include Sting activator, polypeptide radioactive element complex, etc., teri vasopressin and its injection will be submitted for new drug registration application, and Ciconotone and Linalotide will be applied f
● Jiangsu Hanpeptide Biomedicine Co., LTD., registered by Hanpeptide Biomedicine Group Co., LTD., is located in Donghai County, Lianyungang, the bridgehead of the beautiful and rich Eurasian continent.The company's business scope includes
● At the beginning of 2020, the company signed a cooperation agreement with Gaoqing Economic Development Zone of Zibo, planning to build polypeptide API production lines, polyglutamic acid and hyaluronic acid production lines, etc.
On May 28, 2020, "Shandong Hanpeptide Biomedicine Co., LTD. - Shandong University Research and Development Team Cooperation Exchange Meeting"[2020-08-14]
Based on the principle of "complementary advantages, mutual benefit, serving local communities and common development", Shandong Hanpeptide[2020-08-14]
As of 22 July, the viral epidemic of Novel Coronavirus has affected over 200 countries worldwide and has been confirmed15007683614805People were kille[2020-08-14]
版权所有 © 汉肽生物医药集团 鲁ICP备069573500456号
Scan follows the public account